| Literature DB >> 34980218 |
Ricardo Pérez-Sánchez1, Angel Carnero-Morán2, M Luz Valero3, Ana Oleaga.
Abstract
BACKGROUND: The argasid tick Ornithodoros erraticus is the main vector of tick-borne human relapsing fever (TBRF) and African swine fever (ASF) in the Mediterranean Basin. The prevention and control of these diseases would greatly benefit from the elimination of O. erraticus populations, and anti-tick vaccines are envisaged as an effective and sustainable alternative to chemical acaricide usage for tick control. Ornithodoros erraticus saliva contains bioactive proteins that play essential functions in tick feeding and host defence modulation, which may contribute to host infection by tick-borne pathogens. Hence, these proteins could be candidate antigen targets for the development of vaccines aimed at the control and prevention of O. erraticus infestations and the diseases this tick transmits. The objective of the present work was to obtain and characterise the proteome of the saliva of O. erraticus adult ticks as a means to identify and select novel salivary antigen targets.Entities:
Keywords: LC–MS/MS; Ornithodoros erraticus; Proteome; Proteomics; SWATH-MS; Saliva; Soft ticks
Mesh:
Substances:
Year: 2022 PMID: 34980218 PMCID: PMC8722417 DOI: 10.1186/s13071-021-05118-1
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Fig. 1Schematics of experimental workflow employed in this study
Fig. 2a Silver-stained 5–20% SDS-PAGE gel showing replicated samples of saliva (4 µg/lane) from female (F1, F2, F3) and male (M1, M2, M3) Ornithodoros erraticus ticks. b Coomassie Blue-stained 5–20% SDS-PAGE gel showing pooled female saliva (F1 + F2 + F3). The gel lane was sliced into the three pieces, and the resulting gel slices (S1, S2, S3) were digested with trypsin and analysed by LC–MS/MS
Fig. 3Venn diagrams depicting number and overlap of salivary proteins in female and male saliva detected by DDA LC-MS/MS (a) and DDA and SWATH-MS (b)
Number of proteins identified in saliva of Ornithodoros erraticus females and males by LC–MS/MS and SWATH-MS as classified in 24 different functional groups and families
| Classification | LC–MS/MS | SWATH (female + male) | ||
|---|---|---|---|---|
| Adult pool | Female | Male | ||
| Antimicrobial | 2 | 2 | 2 | 2 |
| Antioxidant/detoxificationa | 22 | 12 | 19a | 16 |
| Cytoskeletal | 17 | 14 | 11 | 10 |
| Extracellular matrix | 13 | 11 | 5 | 6 |
| Glycine rich | 3 | 3 | 3 | 3 |
| Heme/iron binding | 11 | 10 | 9 | 10 |
| Immune related | 12 | 10 | 8 | 7 |
| Lipocalina | 25 | 18 | 20a | 16 |
| Metabolism, amino acids | 1 | 1 | 1 | 1 |
| Metabolism, carbohydratesa | 22 | 8 | 20a | 19 |
| Metabolism, energya | 16 | 5 | 14a | 7 |
| Metabolism, lipids | 14 | 10 | 10 | 10 |
| Metabolism, nucleic acidsa | 18 | 11 | 15a | 6 |
| Nuclear regulation | 16 | 13 | 7 | 4 |
| Protease | 44 | 31 | 29 | 24 |
| Protease inhibitor | 32 | 28 | 23 | 26 |
| Proteasome machinery | 8 | 4 | 4 | 1 |
| Protein modification | 9 | 5 | 5 | 5 |
| Protein synthesis | 5 | 4 | 1 | 1 |
| Signal transduction | 11 | 9 | 4 | 5 |
| Transcription machinery | 2 | 1 | 1 | – |
| Transporter/receptors | 22 | 16 | 14 | 11 |
| Transposon element | 3 | 2 | 2 | 1 |
| Unknown function | 59 | 46 | 36 | 33 |
| Total | 387 | 274 | 263 | 224 |
Additional details can be found in Additional file 1: Table S1
aFunctional groups and families containing a higher number of proteins in male than in female saliva
Proteins differentially expressed between female and male saliva
| Functional category | Accession | Description | Mean signal peak area × 103 ( | Mean signal peak area × 103 ( | Fold change (female/male) | |
|---|---|---|---|---|---|---|
| Antimicrobial | ACB70385 | Hebreain-like protein | 95.60 | 313.28 | 0.31 | 1.31E−02 |
| Antioxidant/detoxification | B7PHC3 | Carbon–nitrogen hydrolase, putative | 2086.45 | 320.63 | 6.51 | 3.10E−02 |
| PRD32710 | Mitochondrial amidoxime reducing component 2 | 755.23 | 160.62 | 4.70 | 2.83E−03 | |
| B7PQF4 | Sulfotransferase, putative | 30.34 | 73.69 | 0.41 | 1.86E−02 | |
| B7QGH2 | Glutathione | 161.86 | 495.61 | 0.33 | 6.81E−03 | |
| ABI52820 | Superoxide-dismutase | 99.49 | 325.97 | 0.31 | 1.88E−02 | |
| AWM72026 | Catalase 1 | 716.85 | 2,616.34 | 0.27 | 2.61E−02 | |
| RZF47230 | Hypothetical protein LSTR_LSTR004939 | 84.68 | 684.44 | 0.12 | 3.09E−06 | |
| Cytoskeletal | ABP01547 | beta-Actin | 631.00 | 966.00 | 0.65 | 4.54E−02 |
| Extracellular matrix | AAS01023 | Mucin/peritrophin-like protein precursor | 81.49 | 0.05 | 1,644.20 | 4.72E−02 |
| XP_015907551 | Laminin subunit beta-1 isoform X1 | 123.26 | 0.24 | 524.48 | 4.34E−02 | |
| B7Q2R9 | Cell adhesion molecule, putative | 14.83 | 51.41 | 0.29 | 2.66E−03 | |
| Glycine rich | B7Q6J2 | Glycine proline-rich secreted protein, putative | 2406.02 | 748.22 | 3.22 | 3.30E−02 |
| Heme/iron binding | AXP34687 | Vitellogenin-1 | 6447.77 | 4.84 | 1333.20 | 3.47E−02 |
| AJR36491 | Hemelipoglyco-carrier protein CP3 | 3552.23 | 8.50 | 418.01 | 2.25E−03 | |
| ISCW021710-PA | CP3 | 866.12 | 25.82 | 33.54 | 8.62E−05 | |
| AXP34690 | Vitellogenin-B | 1595.72 | 357.35 | 4.47 | 3.18E−02 | |
| Immune related | B7Q4R4 | Double sized immunoglobulin G binding protein A | 3993.51 | 779.57 | 5.12 | 1.32E−02 |
| DAA34752 | Ixodegrin | 44.01 | 135.43 | 0.32 | 3.96E−02 | |
| AAM54048 | Savignygrin | 92.22 | 1021.83 | 0.09 | 4.38E−06 | |
| Lipocalin | ABI52661 | Lipocalin | 785.86 | 196.68 | 4.00 | 1.10E−04 |
| ACB70384 | Salivary lipocalin | 2161.01 | 667.58 | 3.24 | 3.86E−02 | |
| ACB70386 | Salivary lipocalin, partial | 94.71 | 31.31 | 3.03 | 2.93E−02 | |
| ADI60053 | Savicalin | 2749.89 | 2389.58 | 1.15 | 1.60E−04 | |
| ABR23414 | Moubatin-like 3 | 203.26 | 406.82 | 0.50 | 6.81E−03 | |
| ABI52654 | Monotonin | 1149.91 | 2585.77 | 0.44 | 7.50E−04 | |
| B7QAQ5 | Putative uncharacterised protein (fragment) | 28.73 | 99.58 | 0.29 | 2.29E−03 | |
| ABR23394 | Truncated salivary lipocalin, partial | 15.89 | 84.78 | 0.19 | 2.24E−03 | |
| ABR23399 | Moubatin 1-like 2 | 466.29 | 6239.00 | 0.07 | 2.10E−03 | |
| ABR23443 | Salivary secreted lipocalin | 35.76 | 1031.18 | 0.03 | 2.63E−03 | |
| ABR23457 | Moubatin-like 5 | 12.16 | 5932.07 | 0.00 | 1.12E−03 | |
| Metabolism, amino acids | TDG38496 | Hypothetical protein AWZ03_015082 | 486.14 | 3401.02 | 0.14 | 1.70E−04 |
| Metabolism, carbohydrates | B7QBY6 | Glyoxalase, putative | 41.51 | 96.62 | 0.43 | 1.22E−02 |
| XP_013777447 | Glucose-6-phosphate isomerase | 271.80 | 808.75 | 0.34 | 7.15E−03 | |
| DAA34560 | Malate dehydrogenase | 81.64 | 330.49 | 0.25 | 7.34E−06 | |
| B7PLL4 | Fructose-1,6-bisphosphatase, putative | 128.30 | 534.11 | 0.24 | 1.21E−03 | |
| B7Q0R0 | Phosphoglycerate mutase, putative | 238.67 | 1208.54 | 0.20 | 2.08E−03 | |
| AIW65719 | Phosphoglucomutase, partial | 15.03 | 89.67 | 0.17 | 3.46E−05 | |
| ADD91327 | Enolase | 474.65 | 2936.96 | 0.16 | 2.40E−04 | |
| ISCW015616-PA | 3-Phosphoglycerate kinase, putative | 437.28 | 2707.91 | 0.16 | 1.70E−04 | |
| B7Q3K7 | Tpi description | 240.42 | 1591.72 | 0.15 | 3.25E−05 | |
| ISCW020197-PA | Pyruvate kinase, putative | 273.95 | 3468.12 | 0.08 | 1.74E−03 | |
| ASV64058 | Fructose-1,6-bisphosphate aldolase | 917.27 | 15,028.55 | 0.06 | 1.20E−04 | |
| Metabolism, energy | KDR16306 | Glycogen debranching enzyme, partial | 109.61 | 280.36 | 0.39 | 7.04E−03 |
| ISCW018700-PA | Glyceraldehyde 3-phosphate dehydrogenase, putative | 659.81 | 5964.82 | 0.11 | 1.30E−03 | |
| Metabolism, lipids | KFM77310 | Apolipoprotein B-100, partial | 314.75 | 3.03 | 103.96 | 1.56E−02 |
| ACB70350 | Phospholipase A2, partial | 264.73 | 67.48 | 3.92 | 1.39E−02 | |
| AGJ90343 | Phospholipase A2 | 3359.95 | 3070.84 | 1.09 | 2.13E−03 | |
| ABI52805 | Phospholipase A2, partial | 328.61 | 812.17 | 0.40 | 3.45E−02 | |
| ABR23453 | Phospholipase A2 | 7.81 | 21.19 | 0.37 | 1.15E−02 | |
| CAX51408 | Hypothetical protein, partial | 39.25 | 113.37 | 0.35 | 2.93E−02 | |
| XP_015915960 | Phosphatidylinositol transfer protein alpha isoform | 2.92 | 45.86 | 0.06 | 4.20E−03 | |
| Metabolism, nucleic acids | B7PCV9 | Lysosomal acid phosphatase, putative | 2148.64 | 1148.01 | 1.87 | 5.67E−03 |
| ABS30897 | 5′-Nucleotidase/putative apyrase isoform 2 precursor | 270.86 | 191.26 | 1.42 | 4.18E−03 | |
| AGJ90350 | Apyrase | 232.08 | 234.82 | 0.99 | 3.72E−02 | |
| B7PJJ3 | Adenosine deaminase, putative | 95.83 | 391.27 | 0.24 | 6.30E−04 | |
| Nuclear regulation | AHN53412 | Histone H2B | 7.83 | 22.10 | 0.35 | 3.12E−02 |
| XP_017008549 | Histone H4-like, partial | 2.16 | 33.42 | 0.06 | 4.00E−04 | |
| Protease | B7PF28 | Longipain, putative | 63.26 | 0.13 | 500.99 | 2.57E−02 |
| AMO02552 | Carboxypeptidase Q | 86.22 | 1.90 | 45.40 | 4.53E−02 | |
| ABO26562 | Cathepsin L-like cysteine protease | 659.14 | 131.99 | 4.99 | 1.26E−02 | |
| ISCW004835-PA | Coagulation factor precursor, putative | 294.51 | 60.38 | 4.88 | 2.15E−02 | |
| XP_013774340 | Carboxypeptidase E-like | 270.53 | 117.03 | 2.31 | 3.47E−02 | |
| B7PJ51 | Serine carboxypeptidase, putative (Fragment) | 1492.78 | 648.27 | 2.30 | 1.90E−03 | |
| XP_019696599 | Neprilysin-1 | 97.36 | 43.48 | 2.24 | 2.21E−02 | |
| ABI52714 | Metalloprotease, partial | 450.02 | 211.19 | 2.13 | 3.26E−02 | |
| B7QLA0 | Riddle, putative (fragment) | 1308.48 | 3209.73 | 0.41 | 4.00E−03 | |
| Protease inhibitor | ABI94058 | Serpin-8 precursor | 49.66 | 2.44 | 20.35 | 2.89E−03 |
| XP_015907865 | Hemocytin | 7161.53 | 1838.73 | 3.89 | 4.29E−02 | |
| B7P6X9 | Hemolectin, putative (fragment) | 1431.00 | 1045.88 | 1.37 | 3.44E−02 | |
| KFM64508 | Hemocytin, partial | 631.61 | 667.75 | 0.95 | 4.25E−02 | |
| AAS01022 | Putative thyropin precursor | 2472.52 | 4434.56 | 0.56 | 1.26E−02 | |
| P83516 | Chymotrypsin-elastase inhibitor ixodidin | 382.07 | 759.34 | 0.50 | 2.26E−03 | |
| XP_022121224 | Hemocytin | 70.57 | 173.91 | 0.41 | 4.28E−02 | |
| XP_023217368 | Leukocyte elastase inhibitor A-like isoform X2 | 19.51 | 52.26 | 0.37 | 4.18E−03 | |
| XP_022255312 | Hemocytin-like | 22.22 | 62.06 | 0.36 | 7.08E−03 | |
| ACB70299 | Ixodidin | 16.77 | 89.06 | 0.19 | 1.88E−03 | |
| AAS01021 | Cystatin precursor | 167.09 | 1216.49 | 0.14 | 1.15E−03 | |
| XP_020288964 | Chymotrypsin inhibitor-like | 195.85 | 1493.56 | 0.13 | 1.73E−02 | |
| ACF57858 | Chymotrypsin inhibitor precursor | 233.56 | 3678.45 | 0.06 | 1.37E−03 | |
| Protein modification | B7PWF5 | Heat shock protein 20.5, putative | 113.92 | 5.08 | 22.43 | 4.59E−02 |
| B7PAR6 | Heat shock protein, putative | 222.48 | 1285.43 | 0.17 | 2.46E−03 | |
| Signal transduction | XP_021001474 | Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1 | 158.76 | 8.41 | 18.89 | 7.25E−03 |
| Transporter/receptors | AGQ57038 | Vitellogenin receptor | 651.87 | 25.70 | 25.37 | 3.94E−06 |
| XP_015908566 | Low-density lipoprotein receptor-related protein 2 | 107.78 | 53.93 | 2.00 | 1.88E−03 | |
| XP_018014210 | Very low-density lipoprotein receptor-like | 783.98 | 924.47 | 0.85 | 1.22E−02 | |
| B7PL51 | ML domain-containing protein, putative | 93.47 | 491.13 | 0.19 | 4.30E−04 | |
| Unknown function | XP_023240426 | Synaptogenesis protein syg-2-like | 137.70 | 1.41 | 97.65 | 3.88E−03 |
| ACB70374 | Putative salivary secreted protein, partial | 1704.00 | 91.42 | 18.64 | 2.08E−02 | |
| ABI52697 | 7 cysteine domain | 213.20 | 134.32 | 1.59 | 1.96E−03 | |
| ABR23379 | Salivary basic tailless protein | 1124.06 | 1987.85 | 0.57 | 9.02E−05 | |
| XP_023213207 | Transmembrane protein 241-like | 70.75 | 178.42 | 0.40 | 9.99E−03 | |
| AAS94230 | Unknown secreted protein PK-26 precursor | 13,381.20 | 43,089.64 | 0.31 | 2.25E−02 | |
| ABR23361 | Acid tail salivary protein | 14.64 | 53.69 | 0.27 | 3.47E−03 | |
| B7PLB9 | Secreted protein, putative | 502.91 | 4091.22 | 0.12 | 6.10E−04 | |
| ACB70369 | Acid tail salivary protein | 11.20 | 151.34 | 0.07 | 9.36E−05 | |
| XP_022900755 | S-phase kinase-associated protein 1 | 189.20 | 5274.83 | 0.04 | 2.50E−04 |
aP < 0.05
Fig. 4Expression levels of the identified proteins classified by functional groups and families. The expression level was calculated as the average spectral signal peak area in female (F1, F2, F3) and male (M1, M2, M3) saliva samples. a Comparative expression level between female and male saliva. b, c Pie charts showing the percentage of abundance of each functional group/family in the saliva of females (b) and males (c)
Fig. 5Functional categories containing differentially (P < 0.05) expressed proteins between female and male saliva. Fourteen and 17 categories contained overexpressed proteins in females (orange) and males (blue), respectively. Numbers in parentheses indicate the number of overexpressed proteins in each category. Asterisks indicate functional categories overexpressed only in females (n = 3) or in males (n = 6)